Implementing Dementia Care Management Into Routine Care in the Region Siegen-Wittgenstein
Launched by GERMAN CENTER FOR NEURODEGENERATIVE DISEASES (DZNE) · Sep 1, 2022
Trial Information
Current as of May 06, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving care for people with dementia and mild cognitive impairment by introducing a special program called Dementia Care Management (DeCM) in the Siegen-Wittgenstein region of Germany. This program has been shown to be effective in helping patients but hasn't been used in everyday healthcare until now. The trial aims to see how well this program can be integrated into routine care and its impact on the health and well-being of participants.
To take part in this trial, individuals must be between the ages of 65 and 74, have some level of cognitive impairment, and live in the Siegen-Wittgenstein area. Participants will receive support from specially trained dementia care managers for six months. Researchers will evaluate the effects of this care both right after the program ends and at a later time, looking at how it influences health outcomes for the participants. It's important to note that individuals who are living in care facilities or who cannot communicate effectively will not be eligible for this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • person with cognitive impairment living in household
- • living in the region of Siegen-Wittgenstein
- • written informed consent
- Exclusion Criteria:
- • institutionalisation of person with cognitive impairment
- • lacking sufficient communication skills
About German Center For Neurodegenerative Diseases (Dzne)
The German Center for Neurodegenerative Diseases (DZNE) is a leading research institution dedicated to understanding and combating neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). Established to foster innovative research and collaboration, the DZNE integrates clinical and basic research to translate scientific discoveries into effective therapeutic strategies. With a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to advancing knowledge in neurodegeneration, the DZNE actively participates in clinical trials aimed at improving patient outcomes and enhancing the understanding of these complex diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Greifswald, Mv, Germany
Siegen, Nrw, Germany
Siegen, Nrw, Germany
Siegen, Nrw, Germany
Siegen, Nrw, Germany
Witten, Nrw, Germany
Patients applied
Trial Officials
Jochen René Thyrian, Prof. Dr.
Principal Investigator
German Center for Neurodegenerative Diseases (DZNE)
Bernhard Holle, Dr.
Principal Investigator
German Center for Neurodegenerative Diseases (DZNE)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials